by UT Southwestern Medical Center A combination of immunotherapy agents that encourages some immune cells to eat cancer cells and alert others to attack tumors put mice with a deadly type of brain cancer called glioblastoma into long-term remission, a new study led by UT Southwestern scientists suggests. The finding, published online March 20, 2020,...
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice. “While immune checkpoint inhibitors, such as anti-PD1 and anti-CTLA4, are already in clinics and are used mainly as single agents, there are currently almost a thousand clinical...
